Coronary DiseaseGWAScollateralNCT05043948
Genome-wide Association Study of Development of Collateral Circulation for Patients With Coronary or Peripheral Artery Disease
An observational study of Coronary Disease and Peripheral Arterial Disease, run by Jung-min Ahn at 1 site in South Korea.
Trial summary
The purpose of this study is to evaluate the genome-wide association for the development of collateral circulation for patients with coronary or peripheral artery disease and to develop the molecular genetic treatment model based on genome-wide association data. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Coronary Disease, Peripheral Arterial Disease, Collateral Circulation, Any Site
- What is being tested?
- Blood samples
- How many people
- 400 participants
- Where
- 1 siteSouth Korea
- Study dates
- 21 Aug 2015to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with chronic total coronary or peripheral occlusion
Who may be able to join
- Age more than 20
- Chronic total occlusive lesion from the coronary or peripheral angiogram
Who cannot join
- Renal dysfunction
- Hepatic dysfunction
- Thrombocythemia or thrombocythemia
- Planned major surgery in 1 year
- History of gastrointestinal haemorrhage
- Malignant tumor
Trial locations and contacts
1 site in 1 country.
South Korea1 site, 1 recruiting
- Recruiting
Asan Medical Center
Seoul
Jung-min Ahn, MD, drjmahn@gmail.com
Jung-min Ahn, MD
About this study
The purpose of this study is to evaluate the genome-wide association for the development of collateral circulation for patients with coronary or peripheral artery disease and to develop the molecular genetic treatment model based on genome-wide association data.
- Being tested
- Blood samples
- Keywords
- Genome-wide association, Collateral circulation
- Medical subject headings
- Coronary Disease, Peripheral Arterial Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood samplesDiagnostic test
for evaluation of the genome-wide association study
| Study group | Role | What they receive |
|---|---|---|
| Coronary Artery Disease_collateral flow grade 2 | Not described Receives: Diagnostic Test: Blood samples | |
| Coronary Artery Disease_collateral flow grade 0 | Not described Receives: Diagnostic Test: Blood samples | |
| Peripheral Artery Disease_collateral flow grade 2 | Not described Receives: Diagnostic Test: Blood samples | |
| Peripheral Artery Disease_collateral flow grade 0 | Not described Receives: Diagnostic Test: Blood samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between genome and collateral flow
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2021
- Study start21 Aug 2015
- Primary completion30 Jun 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jung-min Ahn
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jung-min Ahn, Asan Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05043948
- Sponsor's protocol ID
- GWAS_collateral
- Acronym
- GWAScollateral
- Status last verified
- Sep 2021
- First submitted
- 12 Sep 2021
- Last updated
- 14 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genome-wide Association Study of Development of Collateral Circulation for Patients With Coronary or Peripheral Artery Disease
- ClinicalTrials.gov ID
- NCT05043948
- Acronym / sponsor ID
- GWAScollateral / GWAS_collateral
- Keywords
- Genome-wide association, Collateral circulation
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Jung-min AhnUniversity, hospital or other
- Study start
- 21 Aug 2015 (actual)
- Primary completion
- 30 Jun 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 14 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the genome-wide association for the development of collateral circulation for patients with coronary or peripheral artery disease and to develop the molecular genetic treatment model based on genome-wide association data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Coronary Artery Disease_collateral flow grade 2 | – | Diagnostic Test: Blood samples |
| Coronary Artery Disease_collateral flow grade 0 | – | Diagnostic Test: Blood samples |
| Peripheral Artery Disease_collateral flow grade 2 | – | Diagnostic Test: Blood samples |
| Peripheral Artery Disease_collateral flow grade 0 | – | Diagnostic Test: Blood samples |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with chronic total coronary or peripheral occlusion
Key inclusion criteria (2 listed)
- Age more than 20
- Chronic total occlusive lesion from the coronary or peripheral angiogram
Key exclusion criteria (6 listed)
- Renal dysfunction
- Hepatic dysfunction
- Thrombocythemia or thrombocythemia
- Planned major surgery in 1 year
- History of gastrointestinal haemorrhage
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood samplesfor evaluation of the genome-wide association study | Diagnostic test | Coronary Artery Disease_collateral flow grade 0, Coronary Artery Disease_collateral flow grade 2, Peripheral Artery Disease_collateral flow grade 0, Peripheral Artery Disease_collateral flow grade 2 |
Primary outcome
Correlation between genome and collateral flow
Time frame: 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Disease and Peripheral Arterial Disease, run by Jung-min Ahn at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jung-hee Ham, Project manager (82230104728, cvcrc5@amc.seoul.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between genome and collateral flow (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2021.